Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00BVS
|
|||
| Former ID |
DNCL002726
|
|||
| Drug Name |
Tanezumab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Cancer related pain [ICD-11: MG30; ICD-10: R52.1, R52.2] | Phase 3 | [1], [2] | |
| Chronic low back pain [ICD-11: MG30.02] | Phase 3 | [3] | ||
| Neuropathic pain [ICD-11: 8E43.0] | Phase 3 | [3] | ||
| Osteoarthritis [ICD-11: FA00-FA05] | Phase 3 | [3] | ||
| Pain [ICD-11: MG30-MG3Z] | Phase 3 | [3] | ||
| Company |
Pfizer New York, NY
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8415). | |||
| REF 2 | ClinicalTrials.gov (NCT00809783) Extension Study Of Tanezumab In Osteoarthritis. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.